Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.

Autor: Kuiper JL; Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Hashemi SM; Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Thunnissen E; Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Snijders PJ; Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Grünberg K; Department of Pathology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands., Bloemena E; Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Sie D; Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Postmus PE; Clatterbridge Cancer Centre and Liverpool Heart & Chest Hospital, Thomas Drive, Liverpool, Merseyside L14 3PE, UK., Heideman DA; Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Smit EF; Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.; Department of Pulmonary Diseases, The Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2016 Dec 06; Vol. 115 (12), pp. 1504-1512. Date of Electronic Publication: 2016 Nov 22.
DOI: 10.1038/bjc.2016.372
Abstrakt: Background: Data on non-small-cell lung cancer (NSCLC) patients with non-classic epidermal growth factor receptor (EGFR) mutations are scarce, especially in non-Asian populations. The purpose of this study was to evaluate prevalence, clinical characteristics and outcome on EGFR-TKI treatment according to type of EGFR mutation in a Dutch cohort of NSCLC patients.
Methods: We retrospectively evaluated a cohort of 240 EGFR-mutated NSCLC patients. Data on demographics, clinical and tumour-related features, EGFR-TKI treatment and clinical outcome were collected and compared between patients with classic EGFR mutations, EGFR exon 20 insertions and other uncommon EGFR mutations.
Results: Classic EGFR mutations were detected in 186 patients (77.5%) and non-classic EGFR mutations in 54 patients (22.5%); 23 patients with an exon 20 insertion (9.6%) and 31 patients with an uncommon EGFR mutation (12.9%). Median progression-free survival (PFS) and overall survival (OS) on EGFR-TKI treatment were 2.9 and 9.7 months, respectively, for patients with an EGFR exon 20 insertion, and 6.4 and 20.2 months, respectively, for patients with an uncommon EGFR mutation. Patients with a double uncommon EGFR mutation that included G719X/L861Q/S768I had longer PFS and OS on EGFR-TKI treatment compared with patients with a single G719X/L861Q/S768I EGFR mutation (both P=0.02).
Conclusions: In our Dutch cohort, prevalence and genotype distribution of non-classic EGFR mutations were in accordance with previously reported data. The PFS and OS on EGFR-TKI treatment in patients with an uncommon EGFR mutation were shorter compared with patients with classic EGFR mutations, but varied among different uncommon EGFR mutations.
Competing Interests: D Heideman has occasionally been member of the scientific advisory boards of Amgen and Pfizer.
Databáze: MEDLINE
Externí odkaz: